Bio-IT World May 11, 2020
Dyno Therapeutics emerged from stealth mode today and announced partnerships with Novartis and Sarepta Therapeutics to develop gene therapies for eye disease and neuromuscular and cardiovascular disease.
Dyno’s platform—CapsidMap—aims to create disease-specific vectors for gene therapy, explains Eric Kelsic, CEO and one of the six company co-founders. Kelsic and other co-founders worked together in George Church’s lab at Harvard; Dyno has an exclusive option to enter into a license agreement with Harvard University for this technology. Church is also a co-founder of Dyno and Chairman of the company’s Scientific Advisory Board.
“Gene therapy is such a huge opportunity to treat disease; there’s huge unmet need there on the disease front. In addition to that, AAV vectors—it feels like we’re at...
Today's Sponsors
Today's Sponsor